Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, comments on the tolerability and efficacy of quadruplet induction regimens in transplant-eligible and transplant-ineligible patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.